检索结果-南通市图书馆

Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer(2024 edition)

同方期刊数据库人大复印报刊资料评论

在线全文

学校读者我要写书评

暂无评论

Radiation Medicine and Protection 2024年第2期5卷 59-67页

作者： Professional Committee of Radiation Oncology china Anti-Cancer Association Branch ofRadiation Oncology chinese Medical Association Branch of Radiation Oncology TreatmentPhysician chinese Medical Doctor Association Qingsong Pang Jun Wang Zhouguang Hui 不详 Tianjin Medical university Cancer Institute&Hospital Tianjin 300060China the Fourth Hospital of Hebei Medical university Shijiazhuang 050011China National Cancer Center National Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China.

Radiotherapy represents an essential treatment approach for esophageal *** recent years,immunotherapy combined with chemotherapy has become the first-line standard treatment for patients with advanced esophageal *** phase III studies on immunotherapy combined with radiotherapy for locally advanced esophageal cancer are currently *** evidence-based medical data are urgently needed to support the integration of immunotherapy and chemoradiotherapy as a new treatment strategy for patients with locally advanced esophageal *** consensus,formulated based on the latest study results,in-depth research,and thorough discussions,provides a comprehensive set of *** document extensively covers treatment strategies and evaluation methods for radiotherapy combined with immunotherapy across patients with operable esophageal cancer,inoperable locally advanced esophageal cancer,and advanced esophageal ***,common complications and radiation-related issues associated with radiotherapy combined with immunotherapy are discussed,serving as clinical *** expert group comprised members from the Professional Committee of Radiation Oncology,china Anti-Cancer Association,the Branch of Radiation Oncology,chinese Medical Association,and the Branch of Radiation Oncology Treatment Physician,chinese Medical Doctor Association.

关键词： Esophageal squamous cell carcinoma Esophageal adenocarcinoma Immunotherapy Chemoradiotherapy Radiotherapy Expert consensus

chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第3期21卷 251-314页

作者： Chang-Sheng MA Shu-Lin WU Shao-Wen LIU Ya-Ling HAN chinese Society of Cardiology chinese Medical Association Heart Rhythm Committee of chinese Society of Biomedical Engineering Beijing Anzhen Hospital Capital Medical University Guandong Provincial People’s Hospital Shanghai First People’s Hospital General Hospital of Northern Theater Command 不详

Atrial fibrillation(AF)is the most common sustained cardiac arrhythmia,significantly impacting patients’quality of life and increasing the risk of death,stroke,heart failure,and *** the past two decades,there have been significant breakthroughs in AF risk prediction and screening,stroke prevention,rhythm control,catheter ablation,and integrated *** this period,the scale,quality,and experience of AF management in china have greatly improved,providing a solid foundation for the development of guidelines for the diagnosis and management of *** further promote standardized AF management,and apply new technologies and concepts to clinical practice in a timely and comprehensive manner,the chinese Society of Cardiology of the chinese Medical Association and the Heart Rhythm Committee of the chinese Society of Biomedical Engineering have jointly developed the chinese Guidelines for the Diagnosis and Management of Atrial *** guidelines have comprehensively elaborated on various aspects of AF management and proposed the CHA2DS2-VASc-60 stroke risk score based on the characteristics of AF in the Asian *** guidelines have also reevaluated the clinical application of AF screening,emphasized the significance of early rhythm control,and highlighted the central role of catheter ablation in rhythm control.

关键词： prevention sustained diagnosis

chinese national clinical practice guidelines on the prevention,diagnosis,and treatment of early gastric cancer

在线全文

学校读者我要写书评

暂无评论

chinese Medical Journal 2024年第8期137卷 887-908页

作者： Peng Li Ziyu Li Enqiang Linghu Jiafu Ji Society of Digestive Endoscopy of the chinese Medical Association Colorectal Surgery Group of the chinese Medical Association chinese Association of Gastroenterologists&Hepatologists National Clinical Research Center for Digestive Diseases chinese Medical Journal Clinical Practice Guideline Collaborative Department of Gastroenterology Beijing Friendship HospitalCapital Medical UniversityNational Clinical Research Center for Digestive DiseaseBeijing 100050China Department of Gastrointestinal Surgery Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142China Department of Gastroenterology and Hepatology the First Medical CenterChinese People’s Liberation Army General HospitalBeijing 100853China 不详

Background:Gastric cancer is one of the most common malignant tumors in the digestive system in *** comprehensive practice guidelines for early gastric cancer in china are currently ***,we created the chinese national clinical practice guideline for the prevention,diagnosis,and treatment of early gastric ***:This clinical practice guideline(CPG)was developed in accordance with the World Health Organization’s recommended process and with the Grading of Recommendations Assessment,Development,and Evaluation(GRADE)in assessing evidence *** used the Evidence to Decision framework to formulate clinical recommendations to minimize bias and increase transparency in the CPG development *** used the Reporting Items for practice Guidelines in HealThcare(RIGHT)statement and the Appraisal of Guidelines for Research and Evaluation II(AGREE II)as reporting and conduct guidelines to ensure completeness and transparency of the ***:This CPG contains 40 recommendations regarding the prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer based on available clinical studies and *** provide recommendations for the timing of Helicobacter pylori eradication,screening populations for early gastric cancer,indications for endoscopic resection and surgical gastrectomy,follow-up interval after treatment,and other ***:This CPG can lead to optimum care for patients and populations by providing up-to-date medical *** intend this CPG for widespread adoption to increase the standard of prevention,screening,diagnosis,treatment,and follow-up of early gastric cancer;thereby,contributing to improving national health care and patient quality of life.

关键词： Early gastric cancer Prevention Screening Diagnosis Treatment Follow-up

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

在线全文

学校读者我要写书评

暂无评论

chinese Journal of Cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of chinese Pharmaceutical Association(CPA) Hospital Pharmacy Professional Committee of chinese Pharmaceutical Association(CPA) Division of Therapeutic Drug Monitoring of chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of chinese Society of Clinical Oncology(CSCO) Expert Committee on Leukemia of chinese Society of Clinical Oncology(CSCO) Society of Integrative Cardio-Oncology of china Anti-Cancer Association(CACA) chinese Society of Hematology of chinese Medical Association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange Association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 3. members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

2023.chinese national clinical practice guideline on diagnosis and management of Crohn’s disease

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第14期137卷 2024 Jul 2页

作者： Inflammatory Bowel Disease Group, chinese Society of Gastroenterology, chinese Medical Association Inflammatory Bowel Disease Quality Control Center of china Xijing Hospital Air Force Medical University China Peking Union Medical College Hospital China West china Hospital Sichuan University China The First Affiliated Hospital Dalian Medical University China university of Nottingham Ningbo China GRADE Centre United Kingdom The First Affiliated Hospital Sun Yat-sen University China Sir Run Run Shaw Hospital Zhejiang University School of Medicine China Peking university People's Hospital China The Second Affiliated Hospital Zhejiang University School of Medicine China Renmin Hospital Wuhan University China chinese PLA General Hospital China The First Affiliated Hospital Naval Medical University China The Sixth Affiliated Hospital Sun Yat-sen University China The First Affiliated Hospital Anhui Medical University China Zhongshan Hospital Xiamen University China Zhongnan Hospital Wuhan University China The First Hospital of Shanxi Medical university China The Eighth Affiliated Hospital Sun Yat-sen University China Peking university Third Hospital China Peking university First Hospital China Qilu Hospital Shandong University China General Hospital of Eastern Theater Command China Xiangya Hospital Central South University China The Tenth People's Hospital Tongji University China The First Affiliated Hospital Kunming Medical University China Shanghai Pudong New District Zhoupu Hospital China Ruijin Hospital Shanghai Jiao Tong University School of Medicine China Tongji Medical College Huazhong University of Science and Technology China General Hospital of Nanjing Military Command China The Third Xiangya Hospital Central South University China Daping Hospital Chongqing China The Second Xiangya Hospital Central South University China Jiangsu Provincial People's Hospital China The Second Hospital of Hebei Medical university China Nanjing Drum Tower Hospital China Nanfan Hospital Southern Medical University China GRADE Center University of Nottingham Ningbo China The Fifth Affiliated Hospital Zhengzhou University

The role of chinese expert consensus in standardization and improvement of the clinical diagnosis and treatment of inflammatory bowel disease (IBD) is self-evident. As clinical and basic research in china becomes standardized under a better understanding of IBD, more data on chinese patients have become available to develop a consensus and guideline. This guideline, collaboratively developed by the IBD Group, chinese Society of Gastroenterology, incorporates the latest international consensus statements,[1-7] domestic research findings, and practical considerations, as an update based on the 2018 chinese consensus on IBD management.[8] The IBD guideline consists of two parts: ulcerative colitis (UC) and Crohn's disease, and this manuscript presented the UC part. The evidence used in this guideline was collected and analyzed by the standard of guideline, and the contents were organized as problem statements, for clarity. The formulation of this guideline aimed to reflect the latest progress in IBD, providing comprehensive and valuable guidance for the clinical management of IBD.

关键词：

chinese consensus on the diagnosis and treatment of immunoglobulin light-chain cardiac amyloidosis

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

chinese Medical Journal 2024年第2期137卷 127-129页

作者： Kaini Shen Zhuang Tian Yajuan Gao Yining Wang Li Huo Jian Li Yun Zhang Shuyang Zhang On behalf of chinese Society of Rare Diseases and Rare Diseases Branch of china Research Hospital Association Department of Hematology State Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Cardiology State Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Clinical Medicine Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Radiology State Key Laboratory of Complex Severe and Rare DiseasesPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Nuclear Medicine Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear MedicineState Key Laboratory of Complex Severe and Rare DiseasesCenter for Rare Diseases ResearchPeking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100730China Department of Cardiology The Key Laboratory of Cardiovascular Remodeling and Function ResearchChinese Ministry of EducationChinese National Health Commission and Chinese Academy of Medical SciencesThe State and Shandong Province Joint Key Laboratory of Translational Cardiovascular MedicineQilu HospitalCheeloo College of MedicineShandong UniversityJinanShandong 250012China Cardiovascular Disease Research Center of Shandong First Medical university Central Hospital Affiliated to Shandong First Medical UniversityJinanShandong 250013China 不详

Epidemiology of Amyloid Light-Chain Cardiac Amyloidosis(AL-CA)The annual incidence of amyloid light-chain(AL)amyloidosis is 3.5/million,and the incidence in men is slightly higher than that in ***,70%of patients with ... 详细信息

关键词： amyloid cardiac diagnosis

chinese Expert Consensus on Microvascular Protection Strategy During Emergency Percutaneous Coronary Intervention Therapy in Patients With ST-elevation Myocardial Infarction

在线全文

学校读者我要写书评

暂无评论

Cardiology Discovery 2024年第1期4卷 5-14页

作者： chinese Society of Cardiology,chinese Medical Association Editorial Board of chinese Journal of Cardiology Muwei Li Yabin Wang Yaling Han Yun Zhang Feng Cao 不详 Fuwai Central china Cardiovascular Hospital chinese People’s Liberation Army General Hospital General Hospital of Northern Theater Command Qilu Hospital of Shandong university

Microcirculatory dysfunction(CMD)typically occurs in patients with acute ST-segment elevation myocardial infarction during percutaneous coronary intervention,which is associated with more severe myocardial injury and a worse *** the advancement of intracoronary physiology and imaging technology,the prevention and therapeutic interventions of CMD have attracted more ***,relevant guidelines or consensus on CMD are lacking in *** current consensus summarizes the prevention and diagnostic strategies of emergency percutaneous coronary intervention-related CMD and gives suggestions to improve the prognosis of ST-segment elevation myocardial infarction patients based on evidence from recent clinical studies,guidelines,and consensus from international sources.

关键词： Myocardial infarction Microcirculation dysfunction Percutaneous coronary intervention

Expert Consensus on the Prevention and Treatment of Chronic Hepatitis B in Children

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Infectious Diseases & Immunity 2024年第3期4卷 106-120页

作者： chinese Society of Infectious Diseases chinese Medical Association chinese Society of Hepatology chinese Medical Association Group of Infectious Diseases chinese Pediatric Society chinese Medical Association National Clinical Research Center for Infectious Diseases(Beijing) Fu-Sheng Wang Shishu Zhu Min Zhang Jianshe Wang Shuangjie Li Junliang Fu Yuanyuan Li Yuming Guo Jing Li Hongmei Xu Wenxian Ouyang Yuemin Nan Sainan Shu Shuangsuo Dang Xiaoyuan Xu Taisheng Li Jinlin Hou 不详 The Fifth Medical Center of PLA General Hospital Beijing 100039China Fudan university Children’s Hospital Hunan Children’s Hospital Children’s Hospital of Chongqing Medical university Third Hospital Hebei Medical University Tongji Hospital Tongji Medical CollegeHuazhong University of Science and Technology The Second Affiliated Hospital of Xi’an Jiaotong university Peking university First Hospital Peking Union Medical College Hospital Chinese Academy of Medical Sciences&Peking Union Medical College Nanfang Hospital Southern Medical University

The aim of this consensus is to standardize the prevention, diagnosis, and treatment of chronic hepatitis B in children and to achieve the goal of “eliminating viral hepatitis as a major public health threat by 203.” issued by the World Health Organization. Formulated by organized experts of the chinese Society of Infectious Diseases and chinese Society of Hepatology, chinese Medical Association;Group of Infectious Diseases, chinese Pediatric Society, chinese Medical Association;and the National Clinical Research Center for Infectious Diseases (Beijing), the consensus provides the latest evidence and recommendations for the prevention, diagnosis, and treatment of chronic hepatitis B in children.

关键词： Chronic hepatitis B Children Treatment Prevention Consensus

chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations(2023.edition)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese Medical Journal 2024年第9期137卷 1016-1018页

作者： The Society of Cancer Precision Medicine of chinese Anti-Cancer Association The Lung Cancer Expert Group of chinese Medical Association Publishing House Baohui Han Hua Zhong 不详 Department of Respiratory Medicine Shanghai Chest HospitalSchool of MedicineShanghai JiaoTong UniversityShanghai 20030China Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine

Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed“forbidden territory”for immunotherapy.[1]With the continuous generation of evidence,immunotherapy is expected to bring hope for such NSCLC with oncogenic driver mutations after acquired tyrosine kinase inhibitor(TKI)***,given the intricate interplay between driven mutations,targeted therapy,and immune microenvironment,the efcacy of immunotherapy in advanced NSCLC patients with diverse oncogenic driver mutations remains a topic of ongoing *** this context,chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Oncogenic Driver Mutations(2022 edition)wasrst launched in 2022 by the Society of Cancer Precision Medicine of chinese Anti-Cancer Association and the Lung Cancer Expert Group of chinese Medical Journals,aiming to provide standardized treatment guidance for clinical practice.

关键词： immunotherapy cancer lung